ID   K2 [Human thyroid carcinoma]
AC   CVCL_6308
DR   BioSample; SAMN03151644
DR   cancercelllines; CVCL_6308
DR   Cosmic; 928834
DR   Cosmic; 1162846
DR   Cosmic; 1789443
DR   Wikidata; Q54899267
RX   PubMed=9054892;
RX   PubMed=10646882;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
CC   Problematic cell line: Contaminated. Shown to be a GLAG-66 derivative (PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00219.
CC   Population: Caucasian; Italian.
CC   Doubling time: 23 hours (PubMed=9054892).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Derived from site: Metastatic; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=21868764
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 11,12
ST   D18S51: 18
ST   D21S11: 30,31.2
ST   D3S1358: 18
ST   D5S818: 10,11
ST   D7S820: 11
ST   D8S1179: 15
ST   FGA: 21,24
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9918 ! GLAG-66
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
RX   PubMed=9054892; DOI=10.1016/S0360-3016(96)00449-X;
RA   Challeton C., Branea F., Schlumberger M., Gaillard N., de Vathaire F.,
RA   Badie C., Antonini P., Parmentier C.;
RT   "Characterization and radiosensitivity at high or low dose rate of
RT   four cell lines derived from human thyroid tumors.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 37:163-169(1997).
RX   PubMed=10646882; DOI=10.1054/bjoc.1999.0920;
RA   Bounacer A., Schlumberger M., Wicker R., du Villard J.A., Caillou B.,
RA   Sarasin A., Suarez H.G.;
RT   "Search for NTRK1 proto-oncogene rearrangements in human thyroid
RT   tumours originated after therapeutic radiation.";
RL   Br. J. Cancer 82:308-314(2000).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).